Tag Archives: Devices and Research

Better Life Technologies Group Selects Fallbrook Engineering to Develop Prototype for Wireless Glucose Monitoring Device

SAN DIEGO, Calif., Jan. 29, 2016 (SEND2PRESS NEWSWIRE) -- Better Life Technologies Group is pleased to announce that it has selected Fallbrook Engineering in Escondido, Calif. to work on the prototyping of its patent-pending, non-invasive wireless-wearable, Glucose Diagnostic Sensor (GDS), US Patent Pending # 14/933985. In 2014, Better Life Technologies Group received a US Patent Grant under US 8,659,435 B2 for a swim safety system device.

"This is an exciting time," George McKinney, president/CEO of Better Life Technologies Group, says. "We believe that we are on the verge of a great breakthrough with a novel approach to glucose monitoring focusing on analyzing gases emanating from the skin. We expect that our approach will advance medicine globally and benefit millions of diabetics."

Recently acknowledged for his company's work in the area of non-invasive glucose monitoring and other wireless-wearable technologies, McKinney received the Roy L. Clay Sr. Technology Pinnacle Award. Roy L. Clay Sr. was an African-American pioneer of early computers often called, the "Godfather of Silicon Valley."

McKinney was recognized as being one of the "Top 50 Most Important African-Americans in Technology."

Richard Meyst, CEO, Fallbrook Engineering, says, "We are quickly available to respond to any project requirements, providing designs, models, prototypes and tooling, as well as process and equipment development and validation."

Fallbrook Engineering has been the source for conscientious engineering consultation and creative product development support since 1981.

Better Life is actively looking for investors/partners in its effort to globalize this GDS technology.

For more information, contact George McKinney at: betterlifetechnologies@gmail.com or visit: http://www.betterlifetech.net/.

Connect with Mr. McKinney on LinkedIn at: https://www.linkedin.com/in/george-mckinney-0a4b7a66 .

About Better Life Technologies Group, Inc.:

Founded in 2011, Better Life Technologies Group's mission is to bring life-preserving and life-improving technologies to the world.

About Fallbrook Engineering:

Fallbrook Engineering is a medical technology consulting firm that provides contract product design, development, management and engineering services to the healthcare products field.

It facilitates the advanced design of medical products including commercialization services for medical disposables, durables, and instruments used in diagnostics, therapeutics and medical treatments of all kinds.

*IMAGES FOR MEDIA:
(1) Photo 300dpi: Send2Press.com/mediaboom/16-0129-mckinney-300dpi.jpg
(1) Photo Caption: George McKinney, president/CEO, Better life Technologies Group, Inc.

(2) Photo 300dpi: Send2Press.com/mediaboom/16-0129-gds-prootype-300dpi.jpg
(2) Photo Caption: Glucose Diagnostic Sensor (GDS) Prototype.

Media Contact: Cidnee Walker, Better Life Technologies Group, Inc., 619-517-6729, betterlifetechnologies@gmail.com

Twitter: @starcolony8 #diabetes #glucosetest

To view the original version on Send2Press Newswire, visit: https://www.send2press.com/newswire/better-life-technologies-group-inc-selects-fallbrook-engineering-to-develop-prototype-wireless-glucose-monitoring-device-2016-0129-02.shtml.

NEWS SOURCE Better Life Technologies Group, Inc. :: This press release was issued on behalf of the news source (who is solely responsible for its accuracy) by and Copr. © 2016 Send2Press® Newswire, a service of Neotrope®.

MEDITE Cancer Diagnostics, Inc. will present at the SeeThruEquity Healthcare Investor Conference on January 11

ORLANDO, Fla., Jan. 7, 2016 (SEND2PRESS NEWSWIRE) -- MEDITE Cancer Diagnostics, Inc. (OTC:MDIT, the "Company"), specializing in the development, manufacturing, and marketing of molecular biomarkers and premium medical devices for detection, risk assessment and diagnosis of cancer and precancerous conditions announces today that CEO, Michaela Ott and CFO, Robert McCullough will present at the SeeThruEquity First Annual Microcap Healthcare Investor Conference on Monday, January 11, 2016, at the Fairmont San Francisco in San Francisco, Calif.

MEDITE, a USA based company now public through the merger with CytoCore Inc. has emerged as a German manufacturer focused on global sales of cancer diagnostic tools consisting of anatomic pathology, histology and cytology laboratory equipment and supplies. Recent agreements with U.S. distribution partners, Hospital Group Purchasing Organizations along with our Chinese partner UNIC Medical will allow the company to focus growth from historically based European sales to entry into the U.S., Latin America and a burgeoning and untapped Chinese market.

UNIC Medical selling MEDITE's equipment, which is already Chinese FDA registered, and cytology assays and stains is involved with the Chinese government in establishing first time country pathology standards for digitalized computer aided diagnosis of cancer in China, a country of 1.4 billion people with a lack of sufficient number of pathologists. As the company expands consumable cytology sales for cervical and breast cancer worldwide, current profitability should significantly expand as margins increase in the near future.

SeeThruEquity is an equity research and corporate access firm focused on companies with less than $1 billion in market capitalization. SeeThruEquity has initiated coverage on numerous NYSE, NASDAQ, TSX, and OTC companies in a variety of industries including technology, health care, consumer, energy and special situations.

About MEDITE Cancer Diagnostics, Inc.:

MEDITE Cancer Diagnostics, Inc. is a Delaware registered company consisting of wholly-owned MEDITE GmbH a Germany-based company with its subsidiaries. On April 3, 2014, MEDITE was acquired by former CytoCore, Inc. a biomolecular diagnostics company engaged in the design, development, and commercialization of cost-effective cancer screening systems and Biomarkers to assist in the early detection of cancer. By acquiring MEDITE the company changed from solely research operations to an operating company with a well-developed infrastructure, 71 employees in four countries, a distribution network to about 70 countries worldwide, a well-known and established brand name and a wide range of products for anatomic pathology, histology and cytology laboratories.

Forward Looking Statement:

This press release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, regarding future operating performance, events, trends and plans. All statements other than statements of historical fact contained herein, including, without limitation, statements regarding our future financial position, business strategy, budgets, projected revenues and costs, and plans and objectives of management for future operations, are forward-looking statements. Forward-looking statements generally can be identified by the use of forward-looking terminology such as "may," "will," "expects," "intends," "plans," "projects," "estimates," "anticipates," or "believes" or the negative thereof or any variation thereon or similar terminology or expressions. We have based these forward-looking statements on our current expectations and projections about future events. These forward-looking statements are not guarantees and are subject to known and unknown risks, uncertainties and assumptions about us that may cause our actual results, levels of activity, performance or achievements to be materially different from any future results, levels of activity, performance or achievements expressed or implied by such forward-looking statements. Important factors that could cause our actual results to differ from our expectations, include but are not limited to, MEDITE's ability to maintain and grow its revenues, as well as those risk factors that apply to our operations as disclosed in Item 1A of our Report on Form 10-K for the year ended December 31, 2014 and other filings with the Securities and Exchange Commission. Readers are cautioned not to place undue reliance on our forward-looking statements, as they speak only as of the date made. Such statements are not guarantees of future performance or events and we undertake no obligation to disclose any revision to these forward-looking statements to reflect events or circumstances occurring after the date hereof.

For more information please visit: http://www.medite-group.com/.

Investor Contact:
Robert McCullough, Jr. CFO
407-996-9630

*LOGO for media: send2press.com/mediaboom/16-0107-medite-diag-300dpi.jpg

REF: OTCMKTS:MDIT

To view the original version on Send2Press Newswire, visit: https://www.send2press.com/newswire/medite-cancer-diagnostics-inc-will-present-at-the-seethruequity-healthcare-investor-conference-on-january-11-2016-0107-04.shtml.

NEWS SOURCE MEDITE Cancer Diagnostics, Inc. :: This press release was issued on behalf of the news source (who is solely responsible for its accuracy) by and Copr. © 2016 Send2Press® Newswire, a service of Neotrope®.

FDA approves Android for Gmate SMART mobile diabetes monitoring system

NEW YORK, N.Y., Dec. 2, 2015 (SEND2PRESS NEWSWIRE) -- Philosys, the maker of Gmate(R) products, announced today that the U.S. Food and Drug Administration (FDA) has approved clearance for the Gmate SMART Blood Glucose Monitoring System and App for Android(TM). The Gmate SMART is a small, portable blood glucose meter that plugs into the headphone jack of a smartphone and provides fast and accurate blood glucose test results. Together, the Gmate SMART Meter and App turn your smartphone into a mobile blood glucose monitoring system.

The FDA approval of Gmate SMART for Android is another important milestone for Philosys. The Gmate SMART App is now available for both iOS and Android users. This is the next critical step for Gmate mHealth technology.

The Gmate SMART Meter is the size of a quarter and connects to the headphone jack of the smartphone. The Gmate SMART App integrates diabetes management directly to the iOS and Android device, providing better diabetes management including goal setting, graphing and the ability to email or text your blood glucose test results directly to a family member or your healthcare provider. The Gmate SMART App stores an unlimited number of test results electronically with the date and time. A user can also add custom comments, actions or notes to each test result. The Gmate SMART is a faster, smarter way to manage and improve diabetes care. The Gmate SMART App is a free download on the App Store(TM) and Google Play(TM).

According to Mike Tickle, Senior VP of Sales, "As cloud technology grows, Philosys is working to create an App-to-Cloud secure connection in the next generation of updates." This will allow for improved communication and notifications between patients and physicians. The Gmate SMART App can provide appropriate automated responses as determined by the medical team. Adds Tickle, "Not only is Gmate SMART changing diabetes care by improving health and lifestyle, but it's also affordable. Most retail pharmacies are selling both the meter and box of 50 count strips at a low cost."

About Philosys:

Philosys is a manufacturing company that specializes in medical, diagnostics and analytical instruments. The range of services we provide covers the entire product cycle from concept through to manufacture. Philosys' philosophy is to develop cost-effective design and manufacturing solutions that satisfy our customer's vision. For more information and where to buy, visit http://www.gmate.com/.

* PHOTO for media: Send2Press.com/mediaboom/15-1202-gmate-300dpi.jpg

Android is a trademark of Google Inc.

Twitter: @Gmate_SMART #Philosys #diabetesmanagement

To view the original version on Send2Press Newswire, visit: https://www.send2press.com/newswire/fda-approves-android-for-gmate-smart-mobile-diabetes-monitoring-system-2015-1202-01.shtml.

NEWS SOURCE Philosys Inc. :: This press release was issued on behalf of the news source (who is solely responsible for its accuracy) by and Copr. © 2015 Send2Press® Newswire, a service of Neotrope®.

MEDITE Cancer Diagnostics, Inc. Reports a Profitable Third Quarter and Nine Month 2015 Results

ORLANDO, Fla., Nov. 17, 2015 (SEND2PRESS NEWSWIRE) -- MEDITE Cancer Diagnostics, Inc. (OTCQB:MDIT, the "Company" / OTCMKTS:MDIT) specializing in the development, manufacturing, and marketing of molecular biomarkers and premium medical devices for detection, risk assessment and diagnosis of cancer and precancerous conditions announces its third quarter and nine month 2015 results.

The Company reports $2.7 million of revenues and an operating profit of $132,000 for the third quarter. For the nine months ended September 30, 2015, revenues were $7.1 million with an operating loss of $58,000. Comparability between the third quarters and nine month periods ending 2015 and 2014 must consider the dollar's 18 percent appreciation during the latter part of 2014 and 2015, along with the exclusion of $358,000 premerger expenses in the 2014 first quarter related to CytoCore, Inc. Approximately 85 percent of the Company's revenues invoiced in Euro currency are generated by the European subsidiaries and were up approximately 5 percent for the nine month period.

Introduction of innovative new products and significant growth in new markets, such as China and Latin America, have resulted in a record for year-end orders. Third quarter orders were up 75 percent compared to last year.

"We expect the upside trend to continue in 2016 as MEDITE benefits from new worldwide histology and cytology product introductions, recent Chinese FDA approvals for histology products and expected Chinese FDA approval for cytology products," stated CEO Michaela Ott.

About MEDITE Cancer Diagnostics, Inc.:

MEDITE Cancer Diagnostics, Inc. is a Delaware registered company consisting of wholly-own MEDITE GmbH a Germany-based company with its subsidiaries. On April 3, 2014, MEDITE was acquired by former CytoCore, Inc. a biomolecular diagnostics company engaged in the design, development, and commercialization of cost-effective cancer screening systems and Biomarkers to assist in the early detection of cancer. By acquiring MEDITE the company changed from solely research operations to an operating company with a well-developed infrastructure, 71 employees in four countries, a distribution network to about 70 countries worldwide, a well-known and established brand name and a wide range of products for anatomic pathology, histology and cytology laboratories.

Forward Looking Statement:

This press release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, regarding future operating performance, events, trends and plans. All statements other than statements of historical fact contained herein, including, without limitation, statements regarding our future financial position, business strategy, budgets, projected revenues and costs, and plans and objectives of management for future operations, are forward-looking statements. Forward-looking statements generally can be identified by the use of forward-looking terminology such as "may," "will," "expects," "intends," "plans," "projects," "estimates," "anticipates," or "believes" or the negative thereof or any variation thereon or similar terminology or expressions. We have based these forward-looking statements on our current expectations and projections about future events. These forward-looking statements are not guarantees and are subject to known and unknown risks, uncertainties and assumptions about us that may cause our actual results, levels of activity, performance or achievements to be materially different from any future results, levels of activity, performance or achievements expressed or implied by such forward-looking statements. Important factors that could cause our actual results to differ from our expectations, include but are not limited to, MEDITE's ability to maintain and grow its revenues, as well as those risk factors that apply to our operations as disclosed in Item 1A of our Report on Form 10-K for the year ended December 31, 2014 and other filings with the Securities and Exchange Commission. Readers are cautioned not to place undue reliance on our forward-looking statements, as they speak only as of the date made. Such statements are not guarantees of future performance or events and we undertake no obligation to disclose any revision to these forward-looking statements to reflect events or circumstances occurring after the date hereof.

For more information please visit: http://www.medite-group.com/.

Investor Contact:
Robert McCullough, Jr. CFO
407-996-9630

REF: OTCMKTS:MDIT / OTC:MDIT

To view the original version on Send2Press Newswire, visit: https://www.send2press.com/newswire/medite-cancer-diagnostics-inc-reports-a-profitable-third-quarter-and-nine-month-2015-results-2015-1117-05.shtml.

NEWS SOURCE MEDITE Cancer Diagnostics, Inc. :: This press release was issued on behalf of the news source (who is solely responsible for its accuracy) by and Copr. © 2015 Send2Press® Newswire, a service of Neotrope®.

Medical Care Alert Earns a 2014 Angie’s List Super Service Award for Third Year

NORTHVILLE, Mich., March 31, 2015 (SEND2PRESS NEWSWIRE) -- For the third year in a row, Medical Care Alert has earned the coveted Angie's List Super Service Award, reflecting another exemplary year of service provided to members of the consumer review site in 2014.

"We are thrilled to be recognized again for our high level of customer service," said Bryan Stapp, President of Medical Care Alert. "Our team members go to tremendous lengths every single day to deliver the best customer service in the industry. We treat our customers like family, and we protect many of our own family members with our service."

Medical Care Alert is a national provider of emergency medical alert systems for senior citizens, providing 24/7 monitoring and protection in the event of a fall or other emergency situation.

"Only about 5 percent of companies have performed so consistently well enough to earn our Super Service Award," said Angie's List Founder Angie Hicks. "It's a really high standard."

Stapp also noted Medical Care Alert has an overall "A" rating with Angie's List readers, plus an "A+" rating as an Accredited Member of the Better Business Bureau (BBB).

Angie's List Super Service Award 2014 winners have met strict eligibility requirements, which include an "A" rating in overall grade, recent grade, and review period grade; the company must be in good standing with Angie's List, pass a background check and abide by Angie's List operational guidelines.

Service company ratings are updated daily on Angie's List. Companies are graded on an A through F scale in areas ranging from price to professionalism to punctuality.

About Medical Care Alert:

Medical Care Alert's "Help At The Push Of A Button" medical alert monitoring service provides independence and peace of mind for thousands of seniors and their families in all 50 states. Systems cost around $1 day, with nothing to buy and no long term contracts. The company has an A+ rating with the BBB and with Angie's List, and has received the Angie's List Super Service Award for three consecutive years. Learn more at http://www.MedicalCareAlert.com/ .

About Angie's List:

Angie's List helps facilitate happy transactions between nearly 3 million consumers nationwide and its collection of highly-rated service providers in 720 categories of service, ranging from home improvement to health care. Built on a foundation of authentic reviews of local service, Angie's List connects consumers directly to its online marketplace of services from member-reviewed providers, and offers unique tools and support designed to improve the local service experience for both consumers and service professionals.

VIDEO about Medical Care Alert: https://youtu.be/2PtqMDJiL5I .

Twitter: @MedicalCareAlrt

*LOGO for media: Send2Press.com/mediaboom/15-0331-mcalert-300dpi.jpg .

To view the original version on Send2Press Newswire, visit: https://www.send2press.com/newswire/medical-care-alert-earns-2014-angies-list-super-service-award-for-third-year-2015-0331-006.shtml.

NEWS SOURCE Medical Care Alert :: This press release was issued on behalf of the news source (who is solely responsible for its accuracy) by and Copr. © 2015 Send2Press® Newswire, a service of Neotrope®.

New Discovery Opens the Door to Possible Cure for Heart Disease

HUNTINGTON BEACH, Calif., July 21, 2014 (SEND2PRESS NEWSWIRE) -- Larry Weisenthal, M.D., Ph.D., today announced new findings that unravel mysteries about the root cause of atherosclerosis - the narrowing of blood vessels that leads to heart attack and stroke. It is a big step toward developing drugs, possibly in the very near future, that prevent the most common forms of heart disease.

Larry Weisenthal, M.D., Ph.D., is a physician and researcher. He has discovered a previously unknown biological mechanism that accounts for vascular calcification - hardening of the arteries. Dr. Weisenthal has named the new mechanism MCED (pronounced EM-sed). It stands for Massively Calcified Endosome Death. By targeting MCED with new drugs, he feels it should be possible to stop vascular calcification from occurring, even among individuals with high cholesterol.

"Cholesterol levels probably won't matter," says Dr. Weisenthal, "at the end of the day the most important cause of arterial blockage may be the presence or absence of circulating MCED factors."

According to the report, Dr. Weisenthal has discovered that, under some circumstances, artery-forming cells, called endothelial cells, die in a special way that involves release of highly calcified micro-particles. These escape from dying endothelial cells and trigger the body's normal immune response. This causes inflammation within the blood vessel and narrows the opening through which blood flows.

Scientists understand that arteries do not literally become clogged with fat, like sludge in an old sewer pipe. Instead, the wall of the artery undergoes an apparent thickening as part of an inflammatory process. But what causes the inflammation to occur? That is exactly the mystery Dr. Weisenthal has unraveled. He contends that MCED is the cause of arterial inflammation.

Until now, no theory fully explained the perplexing mysteries of heart disease. Why do some people who eat all the "wrong" foods live long, healthy lives while other people whose diets appear ideal have heart problems? Why do some people with sky-high cholesterol counts have squeaky-clean arteries while other people, with "good" cholesterol levels, suffer narrowing of the arteries, heart attack, and stroke? Clearly, cholesterol seems to be a factor but, just as clearly, it is not the most important factor.

According to Dr. Weisenthal, MCED explains everything.

Dr. Weisenthal's laboratory experiments have shown that certain chemicals such as cholesterol can indeed cause MCED to occur - but not in everyone. Dr. Weisenthal has shown that blood drawn from different persons varies widely in the ability to prevent MCED from occurring. He says this probably is due to substances - called factors - that are contained in the blood.

Dr. Weisenthal believes it will be possible to isolate MCED-inhibiting factors in the blood and then develop drugs that mimic them. Conceivably, persons at risk for atherosclerosis could be identified through a simple blood test. Such persons would then receive a daily pill to inhibit MCED and prevent the narrowing of arteries.

"That's the importance of this work," says Dr. Weisenthal, "It answers the most important questions relating to the genesis of atherosclerosis and identifies the target for specific drugs to prevent and treat it."

Importantly, only endothelial cells are subject to this particular form of cell death. No other cell Dr. Weisenthal has tested can be made to die in exactly this way. This is additional, strong support for his theory.

The report is available online at http://biorxiv.org/content/early/2014/07/15/007112 .

The discovery itself and the story behind it are featured at this web address: http://vasocell.com/ .

There is also Facebook page called "MCED Vasocell" at: https://www.facebook.com/vasocell .

About Dr. Larry Weisenthal:

Dr. Larry Weisenthal, M.D., Ph.D. is board-certified in medical oncology and internal medicine. He also holds a Ph.D. degree in Pharmacology Research. Dr. Weisenthal owns a laboratory-based medical practice in which he personalizes chemotherapy treatments for individual cancer patients using a test he developed that shows how each patient's living cancer cells respond when exposed in the laboratory to a broad range of chemotherapy drugs. His laboratory website is http://weisenthalcancer.com/. Dr. Weisenthal is also a researcher, author, lecturer, and Associate Clinical Professor of Medicine at the University of California Irvine.

*PHOTO: Send2Press.com/mediaboom/14-0721-Larry-Weisenthal_300dpi.jpg .

To view the original version on Send2Press Newswire, visit: https://www.send2press.com/newswire/New-Discovery-Opens-the-Door-to-Possible-Cure-for-Heart-Disease_2014-07-0721-002.shtml.

NEWS SOURCE Larry Weisenthal :: This press release was issued on behalf of the news source (who is solely responsible for its accuracy) by and Copr. © 2014 Send2Press® Newswire, a service of Neotrope®.

Leading Edge Veterinary Equipment Introduces a New Ultrasound That’s a Cut Above the Rest

DENVER, Colo., March 25, 2014 (SEND2PRESS NEWSWIRE) -- Leading Edge Veterinary Equipment, a supplier of new and exclusive veterinary medical equipment, is excited to announce the Edan DUS 60 VET Ultrasound from Leading Edge now has even better image resolution. With exclusive patented technology, software algorithms have been improved, dramatically enhancing image quality. Equally exciting is that this improvement is included for the same low price.

The Edan DUS 60 VET is a popular high-performance, portable digital ultrasound. Specifically designed for dog, cat, equine, bovine and ovine assessment, the DUS 60 VET provides robust diagnostic information. It offers a wide array of multi-frequency transducers, provides abundant measurement and calculation software packages and Pulse Wave Doppler capability.

These are just a few of the improvements:
* Improved contrast resolution through phase inversion harmonic imaging.
* Multi-beam technology captures more detailed images throughout the depth of field.
* Speckle reduction removes the "noise" to produce a clearer image.
* More preset exam types increases workflow efficiency.
* Pulse Wave Doppler for cardiac diagnostics.

"We are very excited about the improvements made to the Edan DUS 60 VET. This ultrasound stands out above the rest considering the performance and value for the price," says Scott Hopkins, Account Executive at Leading Edge.

As a single source Veterinary medical equipment company, Leading Edge products are available only through a limited and select group of Distributors. Leading Edge product lines include fluid management, imaging, patient monitoring, microscopy, sterilization and others.

For more information on Leading Edge Veterinary Equipment visit: http://www.leadingedgevet.com/ .

About Leading Edge:

Leading Edge provides Veterinary professionals high-performance, competitively priced, reliable Veterinary medical equipment, backed by world-class support and service. As a single source Veterinary medical equipment company, Leading Edge products are available only through a limited and select group of Distributors, who share in our philosophies and standards of excellence, commitment and service. Learn more at: http://www.leadingedgevet.com/ .

To view the original version on Send2Press Newswire, visit: https://www.send2press.com/newswire/Leading-Edge-Veterinary-Equipment-Introduces-a-New-Ultrasound-That-s-a-Cut-Above-the-Rest_2014-03-0325-003.shtml.

NEWS SOURCE Leading Edge Veterinary Equipment :: This press release was issued on behalf of the news source (who is solely responsible for its accuracy) by and Copr. © 2014 Send2Press® Newswire, a service of Neotrope®.

ImageWorks Corporation/AFP – The Leader in Veterinary Digital Dental Imaging, Acquired

DENVER, Colo., Feb. 4, 2014 (SEND2PRESS NEWSWIRE) -- Blackstone Holdings, LLC (Denver, Colo.) has acquired the veterinary division of ImageWorks Corporation/AFP (Elmsford, N.Y.). The new company will operate as ImageWorks Veterinary. Continuing the "Made in the USA" tradition, all operations and manufacturing have been relocated to Colorado.

AFP was the first company to introduce digital dental imaging to the animal health industry in 2004. ImageWorks Veterinary will continue manufacturing the same trustworthy and easy-to-use products, including the EVA Vet™ digital dental sensor. The new company will have improved focus on world-class customer service, guaranteed product availability and innovation with the introduction of the NewTom 5G VET™, 3D Imaging System™.

The revolutionary NewTom 5G VET, 3D Imaging System™ delivers to veterinarians 360 degrees of high resolution advanced diagnostic information.

"Unlike CT and MRI imaging systems, the NewTom 5G VET has a smaller footprint, is more reasonably priced and affordable to maintain," says David Miller, VP of Business Development, at ImageWorks Veterinary. The system obtains a 3D data set in seconds by projecting a cone shape, low-level X-ray dose, scanning in a single revolution around the patient. Rapid scan time and significantly reduced X-ray exposure benefit the patient and the veterinarian.

"We are very excited about this acquisition because it comes with 30 plus years of experience in imaging solutions and the ability to roll out ground-breaking new technology. Our corporate tagline describes our culture and the way we do business: 'Dental imaging equipment you can trust.' Our goal is to solidify our position of leadership in the veterinary dental imaging market. We encourage you to give us an opportunity to earn your business," says Miller. "Since the acquisition, our customers have already seen an improved level of quality and customer service."

For more information on ImageWorks Veterinary Equipment, visit: http://imageworksveterinary.com/ .

ImageWorks Veterinary manufactures high quality, affordable, easy to use dental imaging equipment. Its products include EVA Vet™ digital dental sensors, Image-Vet™ 4G and Image-Vet DC™ intra-oral x-ray systems, and the NewTom 5G VET 3D Imaging System™. ImageWorks Veterinary has the experience of over 15,000 installations worldwide supported by world-class service. Learn more at http://imageworksveterinary.com/ .

Media Contact:
Li Quach
Marketing Manager, ImageWorks Veterinary
li@conquest-one.com

IMAGES - 300dpi for media:
1: NewTom 5G Vet Table
https://www.send2press.com/mediaboom/14-0204-5g-table_300dpi.jpg .

2: Image-Vet X-Ray Systems
https://www.send2press.com/mediaboom/14-0204-image-vet-dc_300dpi.jpg .

3: EVA Vet digital dental sensor
https://www.send2press.com/mediaboom/14-0204-eva-vet_300dpi.jpg .

To view the original version on Send2Press Newswire, visit: https://www.send2press.com/newswire/ImageWorks-Corporation-AFP-The-Leader-in-Veterinary-Digital-Dental-Imaging-Acquired_2014-02-0204-002.shtml.

NEWS SOURCE ImageWorks Veterinary :: This press release was issued on behalf of the news source (who is solely responsible for its accuracy) by and Copr. © 2014 Send2Press® Newswire, a service of Neotrope®.

Leading Edge Veterinary Equipment Signs New Distributor, Midwest Veterinary Supply

DENVER, Colo., Dec. 16, 2013 (SEND2PRESS NEWSWIRE) -- Leading Edge Veterinary Equipment, an international supplier of new and exclusive veterinary medical equipment, announce their agreement with Midwest Veterinary Supply as the newest authorized distributor of Leading Edge products. Midwest Veterinary Supply is one of the country's premier animal health companies, recently celebrating its 50th Anniversary.

This partnership allows Leading Edge to further expand its market presence across North America. With a sales force of over 100 representatives, Midwest Veterinary Supply will now be adding a suite of more than 20 exclusive veterinary medical products to its equipment offerings, with more Leading Edge products coming to market in the near future.

"We are pleased to have Midwest Veterinary Supply as one of our exclusive distributors to help us deliver essential products to the veterinarian that 'Do more and Cost less'," says Scott Hopkins, Account Executive of Leading Edge Veterinary Equipment. "We're setting a new standard in medical equipment for the Veterinary professional, integrating innovation and world-class support that leads to improved patient care and a better experience for both the Veterinarian and the pet owner."

As a single source Veterinary medical equipment company, Leading Edge products are available only through a limited and select group of Distributors. Leading Edge product lines include fluid management, imaging, patient monitoring, microscopy, sterilization and others.

For more information on Leading Edge Veterinary Equipment visit: http://www.leadingedgevet.com/ .

Leading Edge provides Veterinary professionals high-performance, competitively priced, reliable Veterinary medical equipment, backed by world-class support and service. As a single source Veterinary medical equipment company, Leading Edge products are available only through a limited and select group of Distributors, who share in our philosophies and standards of excellence, commitment and service. Learn more at: http://www.leadingedgevet.com/ .

Original syndication source of this press release: http://i.send2press.com/eVE4D .

To view the original version on Send2Press Newswire, visit: https://www.send2press.com/newswire/Leading-Edge-Veterinary-Equipment-Signs-New-Distributor-Midwest-Veterinary-Supply_2013-12-1216-004.shtml.

NEWS SOURCE Leading Edge Veterinary Equipment :: This press release was issued on behalf of the news source (who is solely responsible for its accuracy) by and Copr. © 2013 Send2Press® Newswire, a service of Neotrope®.

ScoopCloud

The affordable PR newswire service